GSK's Studies on Depemokimab for Nasal Polyps Meet Primary Goals

GSK plc (GSK) announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP). The studies evaluated the safety and efficacy of depemokimab versus placebo in adults with CRSwNP, a chronic condition affecting millions globally. The study's co-primary endpoints were to see the change from baseline in total endoscopic nasal polyp score at 52 weeks and the change from baselin ...